2025-08150RuleWallet

Microbial Nucleic Acid Detector Gets FDA Class II Designation

Published Date: 5/9/2025

Rule

Summary

The FDA is officially classifying a special device that detects and identifies tiny germs in patient samples using a cool glowing technique called FISH as a Class II device, meaning it’s safe and effective with some special rules. This change helps get these innovative tools to patients faster by cutting down red tape. The new rules took effect on May 9, 2025, and mainly affect companies making or using these devices in healthcare.

Analyzed Economic Effects

4 provisions identified: 3 benefits, 1 costs, 0 mixed.

FISH Microbial Test Moved to Class II

The FDA officially classified devices that detect microbial nucleic acids by fluorescence in situ hybridization (FISH) in clinical specimens as Class II (special controls). This order is effective May 9, 2025, and the classification was applicable on August 18, 2017. The device is subject to premarket notification under section 510(k) instead of automatic Class III premarket approval.

Required Design Verification and Validation Data

Manufacturers must provide detailed design verification and validation documentation to meet the special controls. Required items include device description, probe sequences and rationale, fluorophore and detection details, analytical studies (limit of detection, inclusivity, reproducibility, interference, cross-reactivity, specimen stability), and a clinical study with prospective (sequential) samples compared to accepted comparator methods.

De Novo Classification Enables Future 510(k) Predicates

Because FDA classified this device into Class II via the De Novo process, the device can serve as a predicate for future devices, allowing later sponsors to use the 510(k) pathway rather than a De Novo request or premarket approval. The FDA notes this can reduce regulatory burdens and enhance patient access to innovation.

Labeling Must Clarify Use and Limits

Device labeling must state the test is to be used along with clinical history, signs, symptoms, and other diagnostic tests. Labels must also explain how to interpret results and quality-control acceptance criteria, and must state that negative results do not rule out infection.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
5/9/2025
5/9/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register